Hengrui Pharma: Injectable SHR-A1811 and other drugs approved for clinical trials

智通財經
2025.06.05 08:14

恆瑞醫藥及其子公司近日獲得國家藥監局批准，開展注射用 SHR-A1811、阿得貝利單抗注射液和蘋果酸法米替尼膠囊的臨牀試驗。具體研究為注射用 SHR-A1811 聯合抗腫瘤藥物治療實體瘤的開放、多中心Ⅰb/Ⅱ期臨牀研究。

智通財經 APP 訊，恆瑞醫藥 (600276.SH) 發佈公告，近日，公司及子公司蘇州盛迪亞生物醫藥有限公司、上海盛迪醫藥有限公司收到國家藥品監督管理局 (簡稱 “國家藥監局”) 核准簽發關於注射用 SHR-A1811、阿得貝利單抗注射液、蘋果酸法米替尼膠囊的《藥物臨牀試驗批准通知書》，將於近期開展臨牀試驗。具體為：注射用 SHR-A1811 聯合抗腫瘤藥物治療實體瘤的開放、多中心Ⅰb/Ⅱ期臨牀研究。

Source: 智通財經 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.